BioXcel Therapeutics (BTAI) Current Assets (2017 - 2026)

BioXcel Therapeutics' Current Assets history runs 10 years deep, the most recent figure standing at $33.9 million for Q1 2026.

• In Q1 2026, Current Assets fell 10.24% year-over-year to $33.9 million; the TTM figure through Mar 2026 stood at $33.9 million (down 10.24% YoY), while the FY2025 annual figure was $44.7 million, up 19.5% from the prior year.
• Current Assets was $33.9 million for Q1 2026 at BioXcel Therapeutics, down from $44.7 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $244.9 million in Q2 2022 to a low of $25.2 million in Q2 2025.
• Historically, Current Assets has averaged $105.9 million across 5 years, with a median of $72.1 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Current Assets slumped 64.44% in 2023, then grew 19.5% in 2025.
• A 5-year view of Current Assets shows it stood at $202.9 million in 2022, then plunged by 64.44% to $72.1 million in 2023, then slumped by 48.17% to $37.4 million in 2024, then advanced by 19.5% to $44.7 million in 2025, then retreated by 24.12% to $33.9 million in 2026.
• The last three Current Assets figures came in at $33.9 million (Q1 2026), $44.7 million (Q4 2025), and $44.4 million (Q3 2025), per Business Quant data.